CHANTILLY, Va., Dec. 1, 2016 /PRNewswire/ -- Intersections Inc. (NASDAQ: INTX), a leading provider of identity risk management, privacy protection and other subscription based services for consumers, today announced that its Board of Directors approved the closure of its Pet Health Monitoring business, known as Voyce®, effective immediately. The Company's subsidiary, i4c Innovations Inc. created Voyce®, an innovative animal health monitoring device that was marketed to pet owners and veterinarians. The discontinuation of Voyce® commercial operations will enable the Company's strategy and capital to be directed toward identity and privacy protection services. Despite interest from leaders in the veterinary industry in the Voyce® pet health monitoring technology, enrollment in the veterinary monitoring program was slower than expected and therefore the Voyce® business was unable to achieve an acceptable level of revenue. The Company is in the process of identifying all of the potential costs and other charges associated with its shutdown of the Pet Health Monitoring business. Additional information will be provided in the forthcoming Form 8-K to be filed with the Securities and Exchange Commission. Michael Stanfield, Intersections Chairman and CEO, stated, "The Voyce® venture was formulated to diversify Intersections' opportunities. Efforts at Voyce® have taken longer than expected, and the time required to introduce such a breakthrough technology to the veterinary market was greater than anticipated. Today, Intersections' principal marketplace - identity and privacy protection - continues to expand and provide significant opportunities for growth. Intersections' new service, Privacy Now™ with Watson, will require intense focus to achieve its maximum potential." Intersections' lender, Crystal Financial LLC, has preliminarily agreed to amend certain provisions of its credit agreement to accommodate the discontinuation and winding down of the Voyce® operations, subject to completion of definitive documentation. The wind down may include the sale of assets and other opportunities to monetize the Voyce® technology. This process may include seeking partners to license the technology for purposes of developing products for the veterinary, pharmaceutical and research markets.